164 related articles for article (PubMed ID: 28301556)
21. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
22. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
24. Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer.
Min EK; Chong JU; Hwang HK; Pae SJ; Kang CM; Lee WJ
World J Gastroenterol; 2017 Jan; 23(4):676-686. PubMed ID: 28216975
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Okada K; Takahashi S; Sueda T
J Surg Oncol; 2018 Dec; 118(7):1105-1114. PubMed ID: 29878355
[TBL] [Abstract][Full Text] [Related]
26. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
[TBL] [Abstract][Full Text] [Related]
27. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
28. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection.
Lee S; Kim SH; Park HK; Jang KT; Hwang JA; Kim S
Radiology; 2018 Aug; 288(2):456-466. PubMed ID: 29664340
[TBL] [Abstract][Full Text] [Related]
31. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.
Zhang Y; Frampton AE; Kyriakides C; Bong JJ; Habib N; Ahmad R; Jiao LR
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1063-71. PubMed ID: 22392075
[TBL] [Abstract][Full Text] [Related]
32. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
Van den Broeck A; Sergeant G; Ectors N; Van Steenbergen W; Aerts R; Topal B
Eur J Surg Oncol; 2009 Jun; 35(6):600-4. PubMed ID: 19131205
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
[TBL] [Abstract][Full Text] [Related]
34. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?
Turner KM; Delman AM; Vaysburg DM; Kharofa JR; Smith MT; Choe KA; Olowokure O; Sohal D; Wilson GC; Ahmad SA; Patel SH
Ann Surg Oncol; 2022 Jun; 29(6):3463-3472. PubMed ID: 35141802
[TBL] [Abstract][Full Text] [Related]
35. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
36. Resolution of new-onset diabetes after radical pancreatic resection predicts long-term survival in patients with pancreatic ductal cell adenocarcinoma.
He XY; Li JF; Yao WY; Yuan YZ
Ann Surg Oncol; 2013 Nov; 20(12):3809-16. PubMed ID: 23943021
[TBL] [Abstract][Full Text] [Related]
37. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
[TBL] [Abstract][Full Text] [Related]
38. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
39. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
[TBL] [Abstract][Full Text] [Related]
40. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Anteby R; Blaszkowsky LS; Hong TS; Qadan M
Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
